CareDx a top pick in diagnostics at Piper Sandler » 05:1006/2906/29/20
Piper Sandler analyst…
Piper Sandler analyst Steven Mah maintains an Overweight rating on CareDx with a $54 price target after taking over coverage of the name. CareDx is one of Piper's top picks in diagnostics. The analyst believes the company has the broadest transplant care platform in the industry and he remains confident that it is well positioned to "protect and extend its first-mover advantage" in both pre- and post-transplant patient management to drive long-term growth. Further, Mah is encouraged by the "resiliency" of its essential tests and ability to operate in a COVID-19 environment.
|Over a week ago|
CareDx initiated with a Buy at BTIG » 07:2106/2606/26/20
BTIG analyst Sung Ji Nam…
BTIG analyst Sung Ji Nam initiated coverage of CareDx with a Buy rating and $40 price target. The company is "redefining" the standard of care for transplant patients by using information gathered through minimally-invasive genomic diagnostic tools, the analyst tells investors in a research note. The current core products of CareDX - AlloSure Kidney and AlloMap Heart - are gaining "strong traction" in the patient surveillance market following kidney and heart transplants, Sung Jim Nam adds, while the company is leveraging its expertise in allo-transplantation to develop more comprehensive solutions to improve transplant patients' outcomes.
CareDx announces publication of study evaluating AlloSure » 07:1906/2206/22/20
CareDx announces that the…
CareDx announces that the journal of the American Society of Nephrology, Kidney360, published a study evaluating AlloSure simultaneously with a different donor-derived cell-free DNA monitoring tool for allograft rejection. This study evaluated 76 kidney transplant patients and surveilled post-transplant kidney rejection utilizing AlloSure and one other dd-cfDNA monitoring tool. Overall, the study found that while there were no significant differences between the diagnostic test characteristics, AlloSure was proven to be more accurate in clinical interpretation and significantly faster in delivering patient results. The study evaluated dd-cfDNA samples and concluded that AlloSure had a significantly superior turnaround time with 75% of the results returned at least one day earlier.
CareDx price target lowered to $37 from $40 at H.C. Wainwright » 06:0606/1906/19/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Yi Chen lowered the firm's price target on CareDx to $37 from $40 and reiterates a Buy rating on the shares.
CareDx announces FDA acceptance of LOI for iBox Scoring System » 07:0206/1806/18/20
The company said,…
The company said, "CareDx congratulates the Critical Path Institute's Transplant Therapeutics Consortium on the U.S. Food and Drug Administration accepting the iBox Scoring System into the Center for Drug Evaluation and Research's Biomarker Qualification Program. TTC provided information supporting the qualification of the iBox Scoring System as a reasonably likely surrogate endpoint for clinical trials evaluating immunosuppressive therapies for use in kidney transplant recipients, allowing drug sponsors to purse accelerated approval. FDA indicated in its decision that it supports TTC's intent to pursue biomarker qualification for the iBox Scoring System and invited TTC to submit a Qualification Plan. CareDx currently offers KidneyCare, which is a prediction tool based on iBox technology, alongside AlloSure and AlloMap, for informing the clinical care and management of transplant patients."
CareDx 3.91M share Secondary priced at $32.00 » 20:1406/1006/10/20
The deal size was…
The deal size was increased from $100M to $125M and priced below the last closing price of $33.51. Goldman Sachs and Jefferies are acting as joint book running managers for the offering.
CareDx files to sell $100M of common stock » 17:1406/0906/09/20
Goldman Sachs & Co.…
Goldman Sachs & Co. and Jefferies are acting as joint book-running managers for the offering. BTIG and Craig-Hallum Capital Group are acting as co-managers for the offering.
CareDx files automatic mixed securities shelf 17:0206/0906/09/20
Seven Bridges announces a new partnership withCareDx » 08:1506/0906/09/20
Seven Bridges announced a…
Seven Bridges announced a new partnership with CareDx supporting the CareDx AlloSure 3.0 workflow. The use of the Seven Bridges Platform and Automation products dramatically speed time to results by streamlining analysis workflows, minimizing the number of manual steps required to set up, run and conclude an analysis. AlloSure is the first clinically and analytically validated, non-invasive donor-derived cell-free DNA, or dd-cfDNA, test for identifying kidney injury. AlloSure can accurately determine active rejection, enabling better management of kidney transplant patients.
|Over a month ago|
CareDx CEO sells 30K share of common stock » 18:2205/1905/19/20
In a regulatory filing,…
In a regulatory filing, CareDx disclosed that its CEO Peter Maag sold 30K shares of common stock on May 19th. The total transaction size was over $967K.